Sarepta Therapeutics, Inc. Earnings Recaps
Q1 2026
May 7, 2026
Shares fell 4.5% after the earnings release as investors reacted negatively to cautious ELEVIDYS growth commentary and a reiterated full-year guidance range that lacked upward revision amid ongoing commercial ramp challenges.
Key takeaways
- Total net product revenue reached $331 million, including $229 million from PMO therapies and $102 million from ELEVIDYS.
- Management emphasized stabilization of marketed products but highlighted the gradual path from patient consideration to infusion for ELEVIDYS.
- Full-year ELEVIDYS revenue guidance was reiterated at $1.2 billion to $1.4 billion, signaling no acceleration despite evidence of clinical benefit.
- Financial position remains solid, with approximately $748 million in cash and investments and positive GAAP and non-GAAP earnings.
- Pipeline progress continues, especially with siRNA programs in DM1, FSHD, and Huntington’s disease, although meaningful impacts remain on the horizon.
Q3 2025
Nov 4, 2025
Sarepta continued to progress toward potential traditional approval for VYONDYS and AMONDYS, completing its confirmatory study while demonstrating a significant, albeit non-statistically significant, treatment benefit in slowing disease progression in Duchenne muscular dystrophy patients.
Key takeaways
- The confirmatory study completed for VYONDYS and AMONDYS showed a meaningful treatment benefit, with a 30% slowing of disease progression when excluding COVID-19 affected participants.
- Despite missing statistical significance, subgroup analyses indicated strong benefits for treatment among likely progressors.
- Continued high patient compliance rates above 90%, despite the demanding infusion protocol, underscored the perceived value of the therapies.
- Sarepta plans to engage with the FDA to discuss transitioning from accelerated to traditional approval based on the totality of available evidence.